Current issue
Volume 53, Issue 4, 2025
Online ISSN: 2560-3310
ISSN: 0350-8773
Volume 53 , Issue 4, (2025)
Published: 30.06.2025.
Open Access
All issues
Contents
01.12.2004.
Case Reports
NEW PHARMACOLOGYCAL APPROACH IN GLAUCOMA TREATMENT USING SOL. XALATAN WHICH IS REGISTERED AS A FIRST CHOICE REMEDY IN EU. Case repport of the high iris insertion.
Trabeculodisgenesis of the primary congenital glaucoma because of the iris affiliate in front of the scleral ridge in
angulus iridocornealis. It is treated both surgically and with medication. We have showed you a patient which has, by the
time of illness diagnosing, developed morphological and functional optic papilla damages. We have applied both
comparative examinations and x-rays before and after sol. Xalatan therapy. With the research which is stillin progress, it is
estabilished that the values of intraocular pressure are brought to statistically normal frame (1,3 kPa-2,9kPa) and the
progression of both eyes´ optic nerves ganglion cells decadance is reduced, too
S. Elek-Vlajić